Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?

Dennis M. Black, Douglas C. Bauer, Ann V. Schwartz, Steven R. Cummings, Clifford J. Rosen

New England Journal of Medicine · 2012 · 277 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

There is controversy over the ideal duration of bisphosphonate therapy for osteoporosis, given reports of atypical subtrochanteric fractures and osteonecrosis of the jaw. But some subgroups of patients may benefit from continuing therapy beyond 3 to 5 years.

References

3